Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FBI investigates Summit-Visx excimer laser scandal

This article was originally published in Clinica

Executive Summary

The scandal involving US laser producers Summit Technology and Visx could prove as damaging to the FDA's reputation as the generic drug scandal of 1989. The House Commerce oversight and investigations subcommittee has held hearings on the allegation that information on Visx' system was leaked from the agency to Summit. The Federal Bureau of Investigation (FBI) is now the lead agency in the affair and if it determines that a Center for Devices & Radiological Health employee did in fact send Summit confidential Visx data, the individual concerned could face three years' imprisonment.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT088770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel